(Q36104939)

12 August 2017

1 reference

title

Angiogenesis and prostate cancer: important laboratory and clinical findings (English)

1 reference

12 August 2017

1 reference

Michael C Cox

1

1 reference

12 August 2017

Matthew Permenter

series ordinal

2

1 reference

12 August 2017

William D Figg

series ordinal

3

1 reference

12 August 2017

publication date

1 May 2005

1 reference

12 August 2017

published in

Current Oncology Reports

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

215-219

1 reference

National Cancer Institute intramural approach to advanced prostate cancer

12 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-005-0076-Z

Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-005-0076-Z

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

21 January 2018

1 reference

12 December 2020

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

1 reference

12 December 2020

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

12 December 2020

ErbB-targeted therapeutic approaches in human cancer

1 reference

12 December 2020

Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2.

1 reference

12 December 2020

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

12 December 2020

Angiogenesis and prostate cancer tumor growth

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Cancer statistics, 2004

1 reference

12 December 2020

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy

1 reference

12 December 2020

Thalidomide metabolism by the CYP2C subfamily.

1 reference

12 December 2020

Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice

1 reference

12 December 2020

Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer

1 reference

12 December 2020

Roles of PPARs in health and disease.

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.

1 reference

12 December 2020

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

12 December 2020

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer

1 reference

12 December 2020

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

1 reference

12 December 2020

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

12 December 2020

An update on prostate cancer

1 reference

12 December 2020

Role of angiogenesis in the progression and treatment of prostate cancer

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis.

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

12 December 2020

Endostatin-mediated concomitant resistance in neuroblastoma

1 reference

12 December 2020

Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450

1 reference

12 December 2020

Significance of angiogenesis in cancer therapy

1 reference

12 December 2020

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues

1 reference

12 December 2020

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.

1 reference

12 December 2020

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

1 reference

12 December 2020

10.1007/S11912-005-0076-Z

Identifiers

DOI

1 reference

12 August 2017

1 reference